Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Analyst: Biopharma Makes 'Right Call' in Stopping Combination Agent in Trial
Research Report

Share on Stocktwits


A Mackie Research Capital Corp. note reviewed recent and upcoming developments in this immunotherapy developer's clinical study.

In a Dec. 13 research note, analyst Andre Uddin reported that IMV Inc. (IMV:TSX; IMMVD:NASDAQ) announced further results from DeCidE1, its Phase 1b/2 study evaluating combination therapy DPX-Survivac plus Incyte's epacadostat in recurrent ovarian cancer.

First, Uddin relayed, results from DeCidE1's Phase 1 led IMV to stop dosing the study participants with either dose of epacadostat, 100 or 300 milligrams. The reasons for the move include the fact that no dose-dependent responses for epacadostat occurred. Additionally, 300 milligrams of epacadostat were associated with lower-surviving specific T cell responses, and the number of study dropouts was significant due to disease progression. "Based on the data disclosed today and previously, we believe IMV made the right call," Uddin indicated.

Another trial phase outcome is that IMV identified a patient subgroup with high responses to the DPX-Survivac/epacadostat combination when using a 5-plus centimeter baseline tumor burden as a biomarker. Uddin wrote that "today's data demonstrated that this subgroup had a 33% overall response rate and [a] disease control rate of 83% versus a 5% overall response rate and a 65% disease control rate of patients with greater than a 5 centimeter baseline tumor burden."

Finally, Uddin noted what investors can expect next from IMV, which is "very key data" from DeCidE1's Phase 2, in which DPX-Survivac will be assessed as a monotherapy in ovarian cancer patients who have a 5-plus centimeter baseline tumor burden. Patient enrollment is currently underway, and preliminary results are expected in Q1/19.

Mackie Research has a Speculative Buy rating and a target price of CA$10.40 per share on IMV. Shares are currently trading at CA$7.33.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from Mackie Research Capital Corp., IMV Inc., Update, December 13, 2018

Relevant disclosures required under IIROC Rule 3400 applicable to companies under coverage discussed in this research report are available on our web site at
1. On January 9, 2015, Andre Uddin visited Immunovaccine’s headquarters and operations in Halifax, and viewed the laboratories, administrative offices, research centres, animal facilities, and small scale manufacturing area. MRCC paid all expenses.
2. MRCC is a market maker of Immunovaccine Inc.

Each analyst of Mackie Research Capital Corporation whose name appears in this report hereby certifies that (i) the recommendations and opinions expressed in this research report accurately reflect the analyst’s personal views and (ii) no part of the research analyst’s compensation was or will be directly or indirectly related to the specific conclusions or recommendations expressed in this research report.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe